Latest Healthtech Startup Funding Rounds
Companies building technology for healthcare delivery, diagnosis, clinical workflows and patient access.
- Rounds
- 752 All time
- Disclosed funding
- $25.4B 616 disclosed amounts
- Median round
- $15.8M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AN Anodyne NanotechCompany profile Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections | $12.6M | Series A | Healthtech, Biotech | United States | Investors | |
| RB RQ BioCompany profile Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients | $115M | Series A | Healthtech, Biotech | United Kingdom | Investors | |
| C CroíValveCompany profile Develops a transcatheter device to treat tricuspid regurgitation in patients with structural heart disease Develops a transcatheter device to treat tricuspid regurgitation in patients with structural heart disease | $27M | Series B | Healthtech | Ireland | Investors | |
| RH Rapalogix HealthCompany profile Develops prescription therapeutics and skincare products for cellular longevity and skin health Develops prescription therapeutics and skincare products for cellular longevity and skin health | $20M | Series A | Healthtech, Biotech | United States | Investors | |
| C Automates chronic care for older adults using AI | $100M | Series CSeries C+ | Healthtech | United States | Investors | |
| NB NorthLinks BioCompany profile Develops broad-spectrum antiviral prophylactic therapies for respiratory infections Develops broad-spectrum antiviral prophylactic therapies for respiratory infections | $34M | Undisclosed | Healthtech, Biotech | United States | Investors | |
| OB Osanni BioCompany profile Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model | $190M | Series B | Healthtech, Biotech | United States | Investors | |
| AS Astral SystemsCompany profile Develops multi-state fusion technology for medical radioisotopes and commercial applications Develops multi-state fusion technology for medical radioisotopes and commercial applications | £23M | Series A | Healthtech, Industrial tech | United Kingdom | Investors | |
| LH Ladder HealthCompany profile Delivers virtual-first AI-enabled pediatric developmental and therapeutic care for children and families Delivers virtual-first AI-enabled pediatric developmental and therapeutic care for children and families | $7M | Seed | Healthtech | United States | Investors | |
| BP Bionyra PharmaCompany profile Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases. Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases. | $165M | Series A | Healthtech, Biotech | France | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1General Catalyst
Baba, Disha (formerly Curelink), Thatch
23rounds2led - 2Y Combinator (YC)
Vitalize, Angle Health, Metriport
21rounds0led - 3Alumni Ventures
MintNeuro, Evvy, Hopscotch Primary Care
13rounds0led - 4Andreessen Horowitz (a16z)
Sharp Performance, General Medicine, Devoted Health
12rounds2led - 5Khosla Ventures
Even Healthcare, Abby Care, Rightway
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.